Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.49 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626818 | 0.84 | ADRA1D (0.61) | TAAR1HRH3HRH4SSTR4SSTR3 | |
| SCHEMBL2741598 | 0.79 | TAAR1 (0.59) | TAAR1HRH3HRH4KMT2A | |
| SCHEMBL8963903 | 0.77 | HRH3 (0.73) | TAAR1HRH3HRH4LMNAKMT2A | |
| SCHEMBL2741584 | 0.76 | TAAR1 (0.54) | TAAR1HRH3HRH4DAOCYP1A2 | |
| SCHEMBL2741588 | 0.76 | TAAR1 (0.54) | TAAR1HRH3HRH4 | |
| SCHEMBL2741601 | 0.76 | TAAR1 (0.54) | TAAR1HRH3HRH4SSTR4SSTR3 | |
| SCHEMBL224745 | 0.74 | TAAR1 (1.00) | TAAR1HRH3HRH4 | |
| SCHEMBL6740216 | 0.74 | TAAR1 (0.71) | TAAR1DAOLMNAKMT2A | |
| SCHEMBL9531175 | 0.74 | CPB2 (0.54) | HRH3HRH4 | |
| SCHEMBL2474964 | 0.73 | CYP19A1 (0.52) | TAAR1HRH3HRH4LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399463-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399463-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | disclosed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | disclosed |
| WO-2008074679-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | TAAR1 1/4885HRH3 194/4885HRH4 142/4885 |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | TAAR1 1/4885HRH3 194/4885HRH4 142/4885 |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | TAAR1 1/4885HRH3 194/4885HRH4 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.